BEAM (Beam Therapeutics) ROCE %: -37.34% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BEAM Beam Therapeutics Inc BEAM
71 GF Score
Price $27.48
GF Value $27.86
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics ROCE %?

Beam Therapeutics BEAM +0.88% 71 ROCE % is -37.34% as of Jun. 2026. GuruFocus rates BEAM with a GF Score™ of 71/100 and a GF Value™ of $27.86 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beam Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2026 was -37.34%.

Beam Therapeutics  (NAS:BEAM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beam Therapeutics ROCE % Related Terms

Beam Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics ROCE % Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -48.74 -28.45 -14.88 -38.20 -33.28

Beam Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.81 -43.25 -5.55 -30.74 -37.34
BEAM
71GF Score
Beam Therapeutics Inc BEAM
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics ROCE % Calculation

Beam Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-383.693/( ( (1103.824 - 182.066) + (1481.177 - 96.935) )/ 2 )
=-383.693/( (921.758+1384.242)/ 2 )
=-383.693/1153
=-33.28 %

Beam Therapeutics's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-506.212/( ( (1480.798 - 74.565) + (1386.355 - 80.883) )/ 2 )
=-506.212/( ( 1406.233 + 1305.472 )/ 2 )
=-506.212/1355.8525
=-37.34 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -37.34% mean?
Beam Therapeutics (BEAM) has a ROCE % of -37.34% as of Jun. 2026.
Is Beam Therapeutics' ROCE % too high?
Beam Therapeutics' current ROCE % is -37.34%. Overall, Beam Therapeutics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' ROCE % compare to KOD and TARS?
Beam Therapeutics' ROCE % of -37.34% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Beam Therapeutics's current ROCE % is -37.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Fairly Valued. The stock's GF Value™ is $27.86, compared to a current price of $27.48 — trading 1.4% below its estimated fair value. The current ROCE % is -37.34%. Beam Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current ROCE % is -37.34% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued. The current stock price of $27.48 is trading 1.4% below its estimated GF Value™ of $27.86. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for BEAM:

  • ROCE %: -37.34%
  • GF Value™: $27.86 vs. price of $27.48 (1.4% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:Mexico
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
71GF Score

Get the complete analysis for BEAM

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.48
Price
$27.86
GF Value